Latest

3 stories

Hide weekly roundups

Friday, August 14

Cellectar registers Phase 3 trial comparing iopofosine I 131 to R-CD in Waldenstrom's

Thursday, August 13

Quarterly updateCellectar Biosciences, Inc.

Cellectar reports Q2 2026 results, advances Phase 3 WM trial toward mid-2027 filing

The company started site activation for a confirmatory Phase 3 study of iopofosine I 131 as it targets an accelerated approval submission and reported $34.0 million in cash.

SEC filing

Friday, July 10

PeopleCellectar Biosciences, Inc.

Cellectar shareholders back share plan increase and warrant exercise vote

At its July 7, 2026 annual meeting, Cellectar Biosciences investors approved a 2,000,000-share increase to the equity incentive plan and a proposal allowing exercise of warrants for up to 39.6 million shares.

SEC filing